Xencor, Inc. (XNCR) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 45.21
30Y Low45.2·High45.9
P/FCF
N/A
—
5yr avg: N/A
30Y Low12.2·High37.7
P/B Ratio
↓
1.44
↓-37% vs avg
5yr avg: 2.27
30Y Low1.8·High8.5
ROE
↓
-14.0%
-12% vs avg
5yr avg: -12.5%
30Y Low-223%·High13%
Debt/EBITDA
N/A
—
5yr avg: 0.66
30Y Low0.6·High0.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
XNCR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Xencor, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $903M | $1.1B | $1.5B | $1.3B | $1.6B | $2.4B | $2.5B | $2.0B | $2.0B | $1.0B | $1.1B |
| Enterprise Value | $1.0B | $1.3B | $1.7B | $1.3B | $1.6B | $2.3B | $2.3B | $2.0B | $1.9B | $1.0B | $1.1B |
| P/E Ratio → | -9.93 | — | — | — | — | 29.28 | — | 74.76 | — | — | 47.00 |
| P/S Ratio | 7.19 | 9.05 | 13.53 | 7.36 | 9.44 | 8.82 | 20.34 | 12.83 | 48.04 | 28.74 | 12.75 |
| P/B Ratio | 1.44 | 1.79 | 2.22 | 1.92 | 2.14 | 3.31 | 4.36 | 3.39 | 3.74 | 3.64 | 3.55 |
| P/FCF | — | — | — | — | — | — | — | 37.70 | — | — | 12.18 |
| P/OCF | — | — | — | — | 63.44 | — | — | 31.23 | — | — | 11.79 |
P/E links to full P/E history page with 30-year chart
XNCR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.12 | 15.26 | 7.53 | 9.47 | 8.42 | 19.11 | 12.58 | 47.39 | 28.27 | 12.58 |
| EV / EBITDA | — | — | — | — | — | 45.21 | — | 108.77 | — | — | 45.87 |
| EV / EBIT | — | — | — | — | — | 28.04 | — | 142.59 | — | — | 23.87 |
| EV / FCF | — | — | — | — | — | — | — | 36.96 | — | — | 12.02 |
XNCR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Xencor, Inc. earns an operating margin of -141.4%. Operating margins have compressed from -75.8% to -141.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -14.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.6% | 91.6% | 100.0% | 100.0% | 100.0% | 100.0% | -38.4% | 24.3% | -140.1% | -101.0% | 40.7% |
| Operating Margin | -141.4% | -141.4% | -161.5% | -75.8% | -50.1% | 15.9% | -62.6% | 8.8% | -195.5% | -150.0% | 25.8% |
| Net Profit Margin | -73.2% | -73.2% | -210.5% | -76.2% | -33.5% | 30.0% | -56.5% | 17.2% | -173.4% | -137.0% | 27.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.0% | -14.0% | -34.6% | -19.1% | -7.6% | 12.7% | -11.9% | 4.8% | -17.5% | -16.4% | 9.9% |
| ROA | -10.1% | -10.1% | -24.4% | -14.8% | -6.6% | 10.7% | -10.1% | 4.3% | -14.6% | -12.0% | 7.4% |
| ROIC | -16.3% | -16.3% | -17.1% | -13.9% | -9.1% | 6.3% | -11.8% | 2.0% | -15.6% | -14.2% | 7.5% |
| ROCE | -21.6% | -21.6% | -20.6% | -16.0% | -10.6% | 6.5% | -13.0% | 2.5% | -19.6% | -17.5% | 9.3% |
XNCR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $134M ($188M total debt minus $54M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.30 | 0.30 | 0.34 | 0.12 | 0.08 | 0.05 | 0.02 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.66 | — | 0.59 | — | — | — |
| Net Debt / Equity | — | 0.21 | 0.28 | 0.04 | 0.01 | -0.15 | -0.27 | -0.07 | -0.05 | -0.06 | -0.05 |
| Net Debt / EBITDA | — | — | — | — | — | -2.14 | — | -2.18 | — | — | -0.61 |
| Debt / FCF | — | — | — | — | — | — | — | -0.74 | — | — | -0.16 |
| Interest Coverage | -1.80 | -1.80 | -5.41 | — | — | 6357.23 | — | — | -4960.63 | -3286.69 | 2197.00 |
XNCR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Xencor, Inc.'s current ratio of 6.25x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.36x to 6.25x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.25 | 6.25 | 6.61 | 7.36 | 10.58 | 6.00 | 5.27 | 8.39 | 5.86 | 2.28 | 1.33 |
| Quick Ratio | 6.25 | 6.25 | 6.61 | 7.36 | 10.58 | 6.00 | 5.27 | 8.39 | 5.86 | 2.28 | 1.33 |
| Cash Ratio | 5.71 | 5.71 | 5.69 | 7.01 | 9.76 | 4.72 | 4.98 | 7.92 | 5.47 | 2.21 | 1.22 |
| Asset Turnover | — | 0.14 | 0.12 | 0.18 | 0.19 | 0.33 | 0.17 | 0.23 | 0.07 | 0.09 | 0.20 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 85.16 | 201.01 | 23.60 | 64.31 | 88.07 | 71.23 | 57.71 | 91.58 | 11.67 | 35.93 |
XNCR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Xencor, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 3.4% | — | 1.3% | — | — | 2.1% |
| FCF Yield | — | — | — | — | — | — | — | 2.7% | — | — | 8.2% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $74M | $65M | $61M | $60M | $60M | $57M | $58M | $54M | $47M | $42M |
Peer Comparison
Compare XNCR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 XNCRYou | $903M | -9.9 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ALKS | $6B | 24.8 | 17.3 | 12.3 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 ZYME | $2B | -24.6 | 0.3 | — | 89.8% | -87.3% | -26.7% | -25.9% | 0.0 |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 INCY | $20B | 15.3 | 11.5 | 14.4 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See XNCR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XNCR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XNCR vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonXNCR — Frequently Asked Questions
Quick answers to the most common questions about buying XNCR stock.
What is Xencor, Inc.'s P/E ratio?
Xencor, Inc.'s current P/E ratio is -9.9x. The historical average is 50.3x.
What is Xencor, Inc.'s ROE?
Xencor, Inc.'s return on equity (ROE) is -14.0%. The historical average is -27.5%.
Is XNCR stock overvalued?
Based on historical data, Xencor, Inc. is trading at a P/E of -9.9x. Compare with industry peers and growth rates for a complete picture.
What are Xencor, Inc.'s profit margins?
Xencor, Inc. has 91.6% gross margin and -141.4% operating margin.